Rivera et al. explored 273 de novo AML patients treated with induction therapy and showed that in these patients, a favorable karyotype and concomitant NPM1 and NRAS mutations were associated with higher CR, ORR, and OS [65]. The gene discussed is NPM1; the disease is acute myeloid leukemia.